Strategic Shape Diagnostic

ET

Enabling Technology

Value accrues by improving someone else’s product. In biopharma, this means delivery and formulation platforms. In devices, it means components and subsystems. In diagnostics, it means sample prep, chemistry, and licensed platforms. The ET shape is fundamentally different from drug development companies because the path to value does not require the ET company to own a clinical program — it requires them to make someone else’s program better.

Deal Structures

How this shape transacts

01

Licensing the platform to pharma or device companies for integration into their products

02

Tool-for-equity partnerships where technology access is exchanged for equity stakes in the partner’s programs

03

Acqui-hire transactions when the technology team is more valuable than the standalone business

04

Platform access agreements with recurring revenue from multiple licensees

Contradictions

Common contradictions for ET companies

Contradiction 01

Trying to become a drug company instead of monetizing the platform — ET companies that pivot into drug development often destroy shareholder value by competing with their own customers

Contradiction 02

Conflating platform improvement value with standalone product value — the technology is valuable because it improves other products, not because it is a product itself

Contradiction 03

Raising drug-development capital for an enabling technology business model

Counterparty View

What counterparties expect

Technology validation matters more than clinical data. Counterparties evaluating ET companies want to see evidence that the technology works in the context of existing products, not standalone clinical results. They look for validated integrations, existing partnerships or pilots, and a clear technical differentiation that justifies switching costs. The acquirer set for ET companies is distinct from drug development companies.

Find out if this is your shape.

The Shape Diagnostic classifies your company into one of seven archetypes in seven minutes.

Take the Diagnostic

Free classification · $49 full report